OM1

Altis Labs announces launch of Nota – a clinical information platform to accelerate therapeutic R&D Nota leverages. AI to predict patient outcomes from imaging data so sponsors can better prioritize their most promising therapies. Nota enables researchers to operationalize clinical trial imaging data, access predictive imaging biomarkers, and accelerate R&D at scale. Using Altis’ cloud-based software platform powered by deep learning, biopharma can incorporate comprehensive outcome predictions at the image, patient, and cohort level to improve clinical trial design and more confidently anticipate clinical endpoints. Such insights have the potential to significantly accelerate development timelines, lower drug development costs, and improve the likelihood of trial success across therapeutic areas.

ConcertAI is a leading provider of AI-powered solutions in the healthcare industry, specializing in oncology. Their mission is to accelerate insights and improve outcomes for patients through leading real-world data, AI technologies, and scientific expertise. ConcertAI offers a suite of products and services designed to enhance clinical research and patient care. Their Real-World Data Products provide comprehensive, fit-for-purpose datasets that support a variety of research needs across the enterprise. The digital trial solution streamlines clinical trial processes, while the Clinical Trial Optimization (CTO) platform utilizes large-scale AI to refine trial design and execution in oncology and hematology. In collaboration with NeoGenomics, ConcertAI has developed CTO-H, a SaaS solution focused on hematological malignancies, offering advanced research analytics and operational optimization.